
Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.
Thomas Morrow, MD, chief medical officer at Next IT, discusses the various difficulties faced by patients when they begin a specialty therapy regimen.
Thomas Morrow, MD, chief medical officer at Next IT, discusses the various difficulties faced by patients when they begin a specialty therapy regimen.
